毛细胞白血病:一种具有独特临床病理特征且分子机制尚未明确的慢性B细胞淋巴瘤
毛细胞白血病(HCL)是一种以全血细胞减少、脾大和肝大为特征的慢性B细胞淋巴增殖性疾病,由「毛状」白血病细胞器官特异性浸润所致。尽管嘌呤类似物和干扰素治疗取得巨大进展,约半数患者初始治疗后复发。BRAF(V600E)突变的发现揭示了驱动HCL B细胞增殖和生存的异常MAPK信号通路,为对髓毒性及免疫抑制药物耐药的患者提供了有前景的治疗靶点。
要点
- 约半数HCL患者初始治疗后复发,尽管嘌呤类似物和干扰素治疗已取得巨大进展。
- BRAF(V600E)突变揭示异常MAPK信号通路驱动HCL B细胞增殖和生存,为耐药患者提供有前景的靶点。
- 已开发2种基于BRAF(V600E)的HCL小鼠模型,可用于功能研究和测试新药活性。
核心结论
- 本文旨在总结当前对HCL发生关键致病机制的理解,并讨论在与其他BRAF突变恶性肿瘤背景下需要克服的主要障碍。
研究设计与样本
- 综述,旨在总结当前对HCL发生关键致病机制的理解,并讨论需克服的主要障碍。
主要发现
- HCL以全血细胞减少、脾大和肝大为特征,由「毛状」白血病细胞器官特异性浸润所致。
- 尽管嘌呤类似物和干扰素治疗取得巨大进展,约半数HCL患者初始治疗后复发。
- HCL中BRAF(V600E)突变的发现揭示了驱动HCL B细胞增殖和生存的异常MAPK信号通路,为对髓毒性及免疫抑制药物耐药的患者提供了有前景且有效的靶点。
- 最近已开发2种基于BRAF(V600E)的HCL小鼠模型,可能对功能研究和测试新药活性极为有用。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Hairy cell leukemia (HCL) is a chronic B-cell lymphoproliferative disorder that is characterized by pancytopenia, splenomegaly, and hepatomegaly, resulting from the organ-specific infiltration of "hairy" leukemic cells. Despite tremendous therapeutic advances with purine analogs and interferon, approximately half of patients with HCL relapse after initial treatment. The discovery of valine-to-glutamic acid mutation at amino acid 600 on B-rapidly accelerated fibrosarcoma [BRAF(V600E)] in HCL, revealed an aberrant MAPK signaling pathway that drives the proliferation and survival of HCL B cells, provides a promising and effective target for treating patients who have developed resistance to myelotoxic and immune-suppressive drugs. More recently, 2 BRAF(V600E)-based HCL mouse models have been developed that could be extremely useful both for functional studies and for testing the activity of new drugs. This review aims to summarize current understanding of key pathogenic mechanisms underlying HCL development and discusses major hurdles that need to be overcome in the context of other BRAF-mutated malignancies.
引用
- Zhang G, Hu J. Hairy cell leukemia: a chronic B-cell lymphoma with unique clinicopathological features and unresolved molecular mechanisms. Blood Adv. 2026. PMID: 41296002. doi:10.1182/bloodadvances.2025017165
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。